Ravandi, F., Ritchie, E. K., Sayar, H., Lancet, J. E., Craig, M. D., Vey, N., … Stuart, R. K. (2015). IMPROVED SURVIVAL IN PATIENTS >= 60 WITH FIRST RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA TREATED WITH VOSAROXIN PLUS CYTARABINE VS PLACEBO PLUS CYTARABINE: RESULTS FROM THE PHASE 3 VALOR STUDY. In HAEMATOLOGICA (Vol. 100, pp. 46–47). Vienna, AUSTRIA: FERRATA STORTI FOUNDATION.

Ravandi, F., E. K. Ritchie, H. Sayar, J. E. Lancet, M. D. Craig, N. Vey, S. A. Strickland, et al. “IMPROVED SURVIVAL IN PATIENTS >= 60 WITH FIRST RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA TREATED WITH VOSAROXIN PLUS CYTARABINE VS PLACEBO PLUS CYTARABINE: RESULTS FROM THE PHASE 3 VALOR STUDY.” In HAEMATOLOGICA, 100:46–47. FERRATA STORTI FOUNDATION, 2015.

Ravandi F, Ritchie EK, Sayar H, Lancet JE, Craig MD, Vey N, et al. IMPROVED SURVIVAL IN PATIENTS >= 60 WITH FIRST RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA TREATED WITH VOSAROXIN PLUS CYTARABINE VS PLACEBO PLUS CYTARABINE: RESULTS FROM THE PHASE 3 VALOR STUDY. In: HAEMATOLOGICA. FERRATA STORTI FOUNDATION; 2015. p. 46–7.

Ravandi, F., et al. “IMPROVED SURVIVAL IN PATIENTS >= 60 WITH FIRST RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA TREATED WITH VOSAROXIN PLUS CYTARABINE VS PLACEBO PLUS CYTARABINE: RESULTS FROM THE PHASE 3 VALOR STUDY.” HAEMATOLOGICA, vol. 100, FERRATA STORTI FOUNDATION, 2015, pp. 46–47.

Ravandi F, Ritchie EK, Sayar H, Lancet JE, Craig MD, Vey N, Strickland SA, Schiller GJ, Jabbour E, Erba HP, Pigneux A, Horst HA, Recher C, Klimek VM, Cortes J, Roboz GJ, Craig AR, Fox JA, Ward R, Smith JA, Acton G, Mehta C, Kantarjian HM, Stuart RK. IMPROVED SURVIVAL IN PATIENTS >= 60 WITH FIRST RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA TREATED WITH VOSAROXIN PLUS CYTARABINE VS PLACEBO PLUS CYTARABINE: RESULTS FROM THE PHASE 3 VALOR STUDY. HAEMATOLOGICA. FERRATA STORTI FOUNDATION; 2015. p. 46–47.